Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rallybio (RLYB) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Rallybio (RLYB) over the last 3 years, with Q3 2025 value amounting to $32.1 million.

  • Rallybio's Cash & Equivalents rose 2686.41% to $32.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.1 million, marking a year-over-year increase of 2686.41%. This contributed to the annual value of $13.9 million for FY2024, which is 4323.92% down from last year.
  • As of Q3 2025, Rallybio's Cash & Equivalents stood at $32.1 million, which was up 2686.41% from $9.4 million recorded in Q2 2025.
  • Rallybio's Cash & Equivalents' 5-year high stood at $39.5 million during Q1 2023, with a 5-year trough of $9.4 million in Q2 2025.
  • Moreover, its 3-year median value for Cash & Equivalents was $19.3 million (2024), whereas its average is $22.5 million.
  • Within the past 5 years, the most significant YoY rise in Rallybio's Cash & Equivalents was 3216.41% (2024), while the steepest drop was 5116.02% (2024).
  • Over the past 3 years, Rallybio's Cash & Equivalents (Quarter) stood at $24.5 million in 2023, then plummeted by 43.24% to $13.9 million in 2024, then skyrocketed by 131.04% to $32.1 million in 2025.
  • Its Cash & Equivalents stands at $32.1 million for Q3 2025, versus $9.4 million for Q2 2025 and $14.8 million for Q1 2025.